CSPC Pharmaceutical Group Limited (CVG) - Total Assets
Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CVG) holds total assets worth €46.70 Billion EUR (≈ $54.59 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CSPC Pharmaceutical Group Limited investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CSPC Pharmaceutical Group Limited - Total Assets Trend (2013–2025)
This chart illustrates how CSPC Pharmaceutical Group Limited's total assets have evolved over time, based on quarterly financial data. Explore CSPC Pharmaceutical Group Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.
CSPC Pharmaceutical Group Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
CSPC Pharmaceutical Group Limited's total assets of €46.70 Billion consist of 47.7% current assets and 52.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.0% |
| Accounts Receivable | €4.78 Billion | 10.2% |
| Inventory | €3.09 Billion | 6.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.77 Billion | 5.9% |
| Goodwill | €234.90 Million | 0.5% |
Asset Composition Trend (2013–2025)
This chart illustrates how CSPC Pharmaceutical Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CSPC Pharmaceutical Group Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC Pharmaceutical Group Limited's current assets represent 47.7% of total assets in 2025, a decrease from 52.2% in 2013.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, up from 9.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
CSPC Pharmaceutical Group Limited Competitors by Total Assets
Key competitors of CSPC Pharmaceutical Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $207.62 Billion |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
CSPC Pharmaceutical Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.19 | 2.27 | 2.53 |
| Quick Ratio | 1.88 | 1.95 | 2.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €12.07 Billion | €12.25 Billion | €9.62 Billion |
CSPC Pharmaceutical Group Limited - Advanced Valuation Insights
This section examines the relationship between CSPC Pharmaceutical Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €46.70 Billion |
| Market Capitalization | $9.80 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CSPC Pharmaceutical Group Limited's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CSPC Pharmaceutical Group Limited's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSPC Pharmaceutical Group Limited (2013–2025)
The table below shows the annual total assets of CSPC Pharmaceutical Group Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €46.70 Billion ≈ $54.59 Billion |
+5.20% |
| 2024-12-31 | €44.39 Billion ≈ $51.90 Billion |
-4.09% |
| 2023-12-31 | €46.28 Billion ≈ $54.11 Billion |
+10.80% |
| 2022-12-31 | €41.77 Billion ≈ $48.83 Billion |
+20.23% |
| 2021-12-31 | €34.74 Billion ≈ $40.62 Billion |
+15.53% |
| 2020-12-31 | €30.07 Billion ≈ $35.16 Billion |
+14.26% |
| 2019-12-31 | €26.32 Billion ≈ $30.77 Billion |
+13.58% |
| 2018-12-31 | €23.17 Billion ≈ $27.09 Billion |
+28.72% |
| 2017-12-31 | €18.00 Billion ≈ $21.05 Billion |
+36.20% |
| 2016-12-31 | €13.22 Billion ≈ $15.45 Billion |
-2.39% |
| 2015-12-31 | €13.54 Billion ≈ $15.83 Billion |
+8.31% |
| 2014-12-31 | €12.50 Billion ≈ $14.62 Billion |
+2.46% |
| 2013-12-31 | €12.20 Billion ≈ $14.26 Billion |
-- |
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more